我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
13
8 进行中
药物批准
5
批准总数
监管机构
2
监管机构数
成立时间
1992
进行中（未招募）
8
61.5%
已完成
3
23.1%
招募中
1
7.7%
NMPA
National Medical Products Administration
CANADA
Health Canada
- Seres Therapeutics has appointed Thomas DesRosier and Marella Thorell as co-CEOs following Eric Shaff's departure after a decade leading the company. - The company is actively engaging with multiple parties for business development partnerships to secure additional capital for advancing SER-155, which showed a 77% relative risk reduction in bloodstream infections. - SER-155 has received FDA Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant. - The leadership transition comes as Seres focuses on expanding SER-155's potential across multiple medically vulnerable patient populations beyond transplant recipients.
